Parecoxib: A shift in pain management?

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 165-177

  Dalpiaz, Anthony S ^a   Peterson, Dave ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Cyclooxygenase 2 inhibitor; Nonsteroidal anti inflammatory drugs; Opioid sparing; Parecoxib; Parenteral; Postoperative pain

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DRUG METABOLITE; FENTANYL CITRATE; FLUCONAZOLE; HEPARIN; IBUPROFEN; KETOCONAZOLE; KETOROLAC; MISOPROSTOL; MORPHINE SULFATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PARECOXIB; PLACEBO; PREDNISONE; PROSTAGLANDIN; ROFECOXIB; SALICYLIC ACID; SC 66905; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB;

ANEMIA; BACKACHE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DENTAL SURGERY; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC SURGERY; HEADACHE; HEALTH CARE COST; HUMAN; HYPERTENSION; INFLAMMATION; INSOMNIA; KIDNEY FAILURE; MUSCLE WEAKNESS; NONHUMAN; OLIGURIA; ORTHOPEDIC SURGERY; PAIN; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHARYNGITIS; PRURITUS; RESPIRATORY FAILURE; REVIEW; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREMOR;

ANIMALS; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOXAZOLES; PAIN; PAIN MEASUREMENT;

EID: 1542374117     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.165     Document Type: Review

References (83)

1. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am. J. Med. 107, S3-S10 (1999).
2. Kaplan-Machlis B, Klostermeyer BS. The cydooxygenase-2 inhibitors: safety and effectiveness. Ann. Pharmacother. 33, 979-988 (1999).
3. Agency for Healthcare Policy and Research. Acute Pain Management: Operative or Medical Procedures and Trauma Clinical Practice Guideline No. 1. AHCPR Publication No. 92-0032 (February 1992). Acute pain guideline.
4. Arthritis Pain Guideline Panel: Simon LS, Lipman AG, Caudill-Slausberg M et al. Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis and juvenile chronic arthritis. Clinical Practice Guideline. American Pain Society. American Pain Society, IL, USA (2002). American Pain Society arthritis guidelines.
5. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 43, 1905-1915 (2000). American College of Rheumarology arthritis guideline.
6. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 39, 713-722 (1996). American College of Rheumatology arthritis guidelines.
7. Bextra® (valdecoxib) tablets package insert. GD Searle LLC, NY, USA (2003).
8. Celebrex® (celecoxib) capsules package insert. GD Searle LLC, NY, USA (2002).
9. Vioxx® (rofecoxib) tablets package insert. Merck & Co. Inc., NJ, USA (2003).
10. Talley JJ, Bertenshaw SR, Brown DL et al. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J. Med Chem 43, 1661-1663 (2000).
11. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 63, 33-45 (2003).
12. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 61, 1133-1143 (2001).
13. Lipsky PE, Brooks P, Crofford LJ et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch. Intern. Med. 160, 913-920 (2000).
14. Lipsky LP, Abramson SB, Crofford L, Dubois RN, Simon LS, van de Putte LB. The classification of cyclooxygenase inhibitors. J. Rheumatol. 25, 2298-2303 (1998).
15. Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. Faseb. J. 12, 1063-1073 (1998).
16. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 43, 4-13 (2000).
17. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. 24(Suppl. 49), 15-19 (1997).
18. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin. Arthritis Rheum. 26, 21-27 (1997).
19. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal antiInflammatory drugs: do they really offer any advantages? Drugs 59, 1207-1216 (2000).
20. Daniels SE, Grossman EH, Kuss ME, Talwalker S, Hubbard RC. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a postoral surgery pain model. Clin. Ther. 23, 1018-1031 (2001). Double-blind trial in oral surgery.
21. Karim A, Laurent A, Slater ME et al. A pharmacokinetic study of intramuscular parecoxib sodium in normal subjects. J. Clin. Pharmacol. 41, 1111-1119 (2001).
22. Hubbard RC, Kuss M, Talwalker S. Evaluation of parecoxib, a new injectable cydooxygenase-2-specific inhibitor, for the treatment of pain. Ann. Emerg. Med 36, S69 (2000).
23. Mehlisch DR, Desjardins PJ, Daniels S, Hubbard RC. Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. J. Oral Maxillofac. Surg. 61, 1030-1037 (2003). Double-blind trial in oral surgery.
24. Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 125, 1481-1492 (2003). Double-blind trial in cardiac surgery.
25. Desjardins PJ, Grossman EH, Kuss ME et al. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth. Analg. 93, 721-727 (2001). Double-blind trial in oral surgery.
26. Hubbard RC, Naumann TM, Traylor L, Dhadda S. Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia. Br. J Anaesth. 90, 166-172 (2003). Double-blind trial in orthopedic surgery.
27. Rasmussen GL, Steckner K, Hogue C, Torri S, Hubbard RC. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery. Am. J. Orthop. 31, 336-343 (2002). Double-blind trial in orthopedic surgery.
28. Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC Parecoxib sodium, a parenteral cyclooxygenase-2 selective inhibitor, improves morphine analgesia and is opioidsparing following total hip arthroplasty, Anesthesiolog 98, 950-956 (2003). Double-blind trial in orthopedic surgery.
29. Tang J, Li S, White PF et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 96, 1305-1309 (2002). Double-blind trial in gynecological surgery.
30. Barton SF, Langeland FF, Snabes MC et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery Anesthesiology. 97, 306-314 (2002). Double-blind trial in gyneoological surgery.
31. Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Br. J. Anaesth. 90, 746-749 (2003). Double-blind trial in gynecological surgery.
32. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: A quantitative systematic review. BMC Anesthesiol. 3, 1 (2003). Systematic review.
33. Bikhazi GB, Bajwa ZH, Snabes MC, LeComte D, Talwalker S, Hubbard RC. Parecoxib effectively treats postlaparotomy pain. Annual Meeting of the American Society for Reproductive Medicine. 481 (2001).
34. Dynastat. European Public Assessment Report (CPMP/1166/02). The European Agency for the Evaluation of Medicinal Products. London. (2002).
35. Dynastat. Summary of Product Characteristics, Pharmacia Europe EEIG. March (2002).
36. Kuss M, Mehlisch D, Bauman A et al. Parecoxib vs. ketorolac: therapeutic use postoperative pain after dental surgery single-dose IV. 9th World Congress on Pain. 3-4 (1999).
37. Kuss M, Mehlisch D, Bauman A et al. Analgesic activity of single IV doses of parecoxib, a COX-2 specific inhibitor and Toradol in postoperative pain. 9th World Congress on Pain 450 (1999).
38. Innes C. Parecoxib: grinding away at dental pain. 9th World Congress on Pain. 7-8 (1999).
39. Mehlisch D, Kuss M, Bauman A et al. Onset and duration of analgesia of single intramuscular doses of parecoxib, a COX-2 specific inhibitor and Toradol in postoperative dental pain. 9th World Congress on Pain 450-451 (1999).
40. Stoltz RR, Harris SI, Kuss ME et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol. 97, 65-71 (2002). Clinical gastrointestinal safety trial.
41. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cydooxygenase-2-specific inhibitor, compared with ketorolac, naproxen and placebo. Clin. Ther. 23, 1422-1428 (2001). Clinical gastrointestinal saky trial.
42. Goldstein JL, Talwalker S, Verburg KM et al. Comparative gastroduodenal mucosal effects of valdecoxib, a potent COX-2 specific inhibitor, compared with naproxen and placebo. Presented at the 9th United European Gastroenterology Week (EUGW). Amsterdam RAI, The Netherlands, October (2001).
43. Goldstein JL, Fakouhi KM, Zhao WW et al. Reduced incidence of gastroduodenal ulcer with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: a multicenter trial. Presented at: Digestive Disease Week Conference. GA, USA. May (2001).
44. Agrawal NM, Paperiello B, Zhao WW et al. Supratherapeutic doses of valdecoxib have reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients, American College of Rheumatology 65th Annual Scientific Meeting. San Francisco, CA, USA. November (2001).
45. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol. Ther. 18, 125-132 (2003).
46. Pavelka K, Recker DP, Verburg, KM Valdecoxib is as effective as didofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatotogy (Oxford). 42, 1207-1215 (2003).
47. Sikes DH, Agrawal NM, Zhao WW. Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur. J. Gastroenterol. Hepatol. 14, 1101-1111 (2002).
48. Menniti-Ippolito F, Maggini M, Raschetti R, Da Cas R, Traversa G, Walker AM. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other nonsteroidal anti-inflammatory drugs in Italy. Eur. J. Clin. Pharmacol. 54, 393-397 (1998).
49. Traversa G, Walker AM, Ippolito FM et al. Gastroduodenal toxicity of different nonsteroidal anti-inflammatory drugs. Epidemiology 6, 49-54 (1995).
50. Quigley EM, Donovan JP, Livingston WC. Ketorolac-related giant gastric ulcers. Am J Gastroenterol. 89, 631-632 (1994).
51. Fuller DK, Kalekas PJ. Ketorolac and gastrointestinal ulceration. Ann. Pharmacother. 27, 978-979 (1993).
52. McEvoy GK. AHFS Drug Informatim American Society of Health System Pharmacists, MD, USA (2003).
53. Toradol® (ketorolac tromethamine) injection package insert. Roche Laboratories Inc., NJ, USA (2002).
54. Drugdex® System. Hutchison TA, Shahan DR (Eds). Micromedex Inc, CO, USA (2003).
55. Woywodt A, Schwarz A, Mengel M, Haller H, Zeidler H, Kohler L. Nephrotoxicity of selective COX-2 inhibitors. J. Rheumatol. 28, 2133-2135 (2001).
56. Graham MG. Acute renal failure related to high-dose celecoxib. Ann. Intern. Med. 135, 69-70 (2001).
57. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Eng. J. Med 343, 1520-1528 (2000).
58. Konstam MA, Weir MR, Reicin A et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104, 2280-2288 (2001).
59. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac and nabumetone). Am J. Cardiol. 89, 204-209 (2002).
60. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284, 1247-1255 (2000).
61. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286, 954-959 (2001).
62. Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A. Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens. 21, 1663-1667 2003).
63. Noveck RJ, Laurent A, Kuss M et al. Parecoxib sodium does not impair platelet function in healthy elderly and nonelderly individuals: two randomized, controlled trials. Clin. Drug Invest. 21, 465-476 (2001). Clinical hematological safety trial.
64. Noveck RJ, Kuss ME, Qian J et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect aspirinmediated platelet function. Region Anaesth. Pain Med 25(Suppl. 2), 19 (2001).
65. Noveck RJ, Kuss ME, Qian J et al. Parecoxib sodium, an injectable COX-2 specific inhibitor, does not affect heparinmediated blood coagulation parametera. Region Anaesth. Pain Med. 26(Suppl.), 20 (2001).
66. Scort LJ, Lamb HM. Rofecoxib. Drugs 58, 499-507 (1999).
67. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J. Clin. Pharmacol. 40, 124-132 (2000).
68. Lesse PT, Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 inhibitor, on platelet function in the elderly. Presented at the European Congress of Rheumatology (EULAR). Prague, Czedi Republic. (2001).
69. Lesse PT, Recker D, Kuss ME. The novel COX-2 inhibitor, valdecoxib, does not affect platelet function in healthy adults. Presented at the European Congress of Rheumatology (EULAR). Prague, Czech Republic. (2001).
70. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects. Arthritis Rheum. 41, 1591-1602 (1998).
71. Kuss HR, Talwalker S, Daniels S. Evaluation of parecoxib a new injectable cyclooxygenase-2-specific inhibitor for the treatment of pain. Ann. Emerg. Med. 36(Suppl. 4), S69 (2000).
72. Harder AT, An YH. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review. J. Clin. Pharmacol. 43, 807-815 (2003).
73. Burd TA, Hughes MS, Anglen JO. Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg. Br 85, 700-705 (2003).
74. Dumont AS, Verma S, Dumont RJ, Hurlbert RJ. Nonsteroidal anti-inflammatory drugs and bone metabolism in spinal fusion surgery: a pharmacological quandary J. Pharmacol. Toxicol. Methods 43, 31 (2000).
75. Matta JM, Siebenrock KA. Does indomethacin reduce heterotopic bone formation after operations for acetabular fractures? A prospective randomised study. J. Bone Joint Surg. Br. 79, 959-963 (1997).
76. Kjaersgaard-Andersen P, Jensen K. Cox inhibitors and bone healing. Acta Orthop. Scand 74, 230-231 (2003).
77. Godden D. Effects of NSAIDs on bone healing have been widely reported in maxillofacial journals. Br. Med. J. 318, 1141 (1999).
78. Gerstenfeld LC, Thiede M, Seibert K et al. Differential inhibition of fracture healing by nonselective and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. J. Orthop. Res. 21, 670-675 (2003).
79. Ibrahim AE, Feldman J, Karim A. Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 98, 853-861 (2003).
80. Ibrahim A, Park S, Feldman J, Karim A, Kharasch ED. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 96, 88-95 (2002).
81. Ibrahim A, Karim A, Feldman J, Kharasch E. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth. Analg. 95, 667-673 (2002).
82. Oderda GM, Evans RS, Lloyd J et al. Cost of opioid-related adverse drug events in surgical patients. J. Pain Symptom Manage. 25, 276-283 (2003).
83. Ng A. Parker J, Toogood L, Cotton BR, Smith G. Does the opioid-sparing effect of rectal diclofenac following total abdominal hysterectomy benefit the patient? Br. J. Anaesth. 88, 714-716 (2002).